Lack of Economic Benefit with Basiliximab Induction in Living Related Donor Adult Renal Transplant Recipients

Abstract

Basiliximab induction therapy did not provide clear clinical efficacy benefit or prove to be cost-effective compared with no induction in LRD recipients.